KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Regeneron Pharmaceuticals (REGN) over the last 17 years, with Q4 2025 value amounting to $8.24.

  • Regeneron Pharmaceuticals' EPS (Basic) fell 351.29% to $8.24 in Q4 2025 from the same period last year, while for Dec 2025 it was $43.15, marking a year-over-year increase of 552.7%. This contributed to the annual value of $43.07 for FY2025, which is 530.56% up from last year.
  • According to the latest figures from Q4 2025, Regeneron Pharmaceuticals' EPS (Basic) is $8.24, which was down 351.29% from $14.09 recorded in Q3 2025.
  • In the past 5 years, Regeneron Pharmaceuticals' EPS (Basic) registered a high of $29.51 during Q2 2021, and its lowest value of $6.7 during Q1 2024.
  • For the 5-year period, Regeneron Pharmaceuticals' EPS (Basic) averaged around $11.9, with its median value being $10.74 (2023).
  • Its EPS (Basic) has fluctuated over the past 5 years, first skyrocketed by 26031.75% in 2021, then tumbled by 7322.94% in 2022.
  • Over the past 5 years, Regeneron Pharmaceuticals' EPS (Basic) (Quarter) stood at $20.98 in 2021, then tumbled by 46.57% to $11.21 in 2022, then decreased by 2.85% to $10.89 in 2023, then decreased by 21.58% to $8.54 in 2024, then fell by 3.51% to $8.24 in 2025.
  • Its EPS (Basic) was $8.24 in Q4 2025, compared to $14.09 in Q3 2025 and $13.24 in Q2 2025.